ASSESSMENT OF INDUCED SPUTUM TO EVAL ANTI-INFLAMMATORY AGENTS IN PTS W/CF

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。炎症有助于囊性纤维化（CF）肺部疾病的进展。CF患者皮质类固醇抗炎治疗已显示出临床益处，但不良反应限制了其使用。CF患者隔天使用皮质类固醇和大剂量布洛芬的临床试验结果表明，抗炎治疗可以减缓衰退的速度。本研究是一项双组、多中心、随机、开放标签、对照、平行组试验，比较轻度至中度CF肺病患者接受28天布洛芬治疗或不接受治疗对诱导痰中炎症介质的影响。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Inflammatory contributes to the progression of cystic fibrosis (CF) lung disease. Anti-inflammatory therapy of corticosteroids in patients with CF have shown clinical benefit, but adverse effects have limited their use. Results from the clinical trials of alternate-day corticosteriods and high-dose ibuprofen in CF indicate anti-inflammatory therapy will slow the rate of decline. This study is a two arm, multicenter, randomized, open-label, controlled, parallel-group trial comparing the effects of 28 days of ibuprofen, or no treatment on inflammatory mediators in induced sputum in subjects with mild to moderate CF lung disease.